COIOSDeep risk insights through multi-disciplinary research across the globe
A store shelf filled with lots of milk
Item refines Peer-reviewed Added

Bariatric operations versus incretin-based therapy in over-65s with type 2 diabetes

In a nationwide cohort of 107,280 adults aged 65 or over with type 2 diabetes and a BMI of 35 or more, bariatric surgery was linked to 23.0% weight loss at 1 year, against 6.87% with incretin-based therapy.

This retrospective cohort compared metabolic and bariatric operations with incretin-based therapy, including GLP-1 receptor agonists. It used Epic Cosmos records on 107,280 adults aged 65 or over with type 2 diabetes and BMI 35 or more. Overlap weighting compared 2,843 operated and 104,437 drug-treated patients, giving most weight to those suited to either. Mean 1-year total weight loss was 23.0% after the operations and 6.87% with incretin-based therapy. Over 5 years, the operations were linked to lower mortality (HR .66), major cardiovascular events (HR .84), nephropathy (HR .73) and retinopathy (HR .65). The design is observational and far fewer patients were operated on, so unmeasured confounding may remain.

Why it is interesting: Long-term comparisons of bariatric operations and incretin-based drugs in older adults have been poorly defined. Here weight loss after the operations was more than three times greater, with fewer cardiometabolic complications and deaths.

Source
Surgery for Obesity and Related Diseases, 19 November 2026
DOI
10.1016/j.soard.2026.10.012
Type
Peer-reviewed article
Design
Retrospective cohort, Epic Cosmos EHR network, adults aged 65+ with T2DM and BMI>=35, n=107,280 (2,843 surgery; 104,437 incretin), 2017-2023, overlap weighting, 1-year weight/HbA1c and 5-year MACE, nephropathy, retinopathy, mortality
Verdict
Refines prior evidence
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today